

JON MCCLELLAN CHILD STUDY AND TREATMENT CENTER







GENERAL DISCLOSURES

The University of Washington School of Medicine also gratefully acknowledges receipt of educational grant support for this activity from the Washington State Legislature through the Safety-Net Hospital Assessment, working to expand access to psychiatric services throughout Washington State.



SPEAKER DISCLOSURES

✓ Research Grants from NIH, NARSAD

✓ No industry grants/consultations/disclosures



OBJECTIVES

- 1. Identify symptoms and patterns of illness characteristics of early onset schizophrenia.
- 2. Recognize clinical presentations of "psychotic-like" symptoms that are more suggestive of nonpsychotic conditions.
- 3. Use evidence-based treatment strategies for schizophrenia



DSM-5 CRITERIA FOR SCHIZOPHRENIA

Two or more characteristic symptoms present for at least one month:

- Hallucinations*
- Delusions*
- Disorganized Speech*
- Disorganized or catatonic behavior
- Negative symptoms

Total duration of illness ≥ 6 months, including significant decline in social or occupational functioning

* DSM-5 requires at least one of these symptoms to make diagnosis



SCHIZOPHRENIA

Epidemiology

- Onset before age 12 years is quite rare.
- Peak ages of onset between 15-30 years
- Males to females ~ 1.4 to 1 in general population
 - Average age of onset for males ~ 5 years younger than females



Diagnostic Evaluation

- Diagnosis made based on:
 - Overt evidence of psychosis, including findings from mental status examination
 - Symptom presentation and course of illness.
 - Review of other potential contributing factors (e.g., substance abuse, medical illnesses)
- Incorporate information from patient, parents, and other resources (schools, other providers)
- Most children reporting psychotic-like symptoms will never develop a psychotic illness

Diagnostic Issues

- High rate of misdiagnosis at onset
 - Differential includes
 - Psychotic mood disorders
 - Schizoaffective disorder
 - Organic psychoses
 - Posttraumatic stress disorder
 - Developmental Disorders, including Autism Spectrum Disorders
 - Personality disorders/traits



Medical Work-up

- Basic pediatric assessment, including neurological exam
- Neuroimaging, laboratory tests:
 - Rule out other conditions or to establish baseline for medication treatment (e.g., liver functions)
 - Tests for specific medical syndromes, e.g. genetic, infectious, autoimmune, rheumatologic, metabolic screens, neuroimaging; based on findings of history and exam (low yield).
- Psychological testing: Useful for treatment/ academic planning, but not for diagnosis



Diagnostic Issues

- Psychotic Symptoms need to be differentiated from:
 - Developmental delays, including speech and language problems.
 - Posttraumatic phenomena.
 - Misinterpretation of the questions.
 - Normal kid weirdness.



PSYCHOTIC-LIKE EXPERIENCES

- ~ 8 % of adolescents (ages 13 to 18 years)
- ~ 17 percent of children (ages 9 to 12 years)
 Describe psychotic-like symptoms
 Psychotic-like experiences associated with increased rates of psychopathology
 - Trauma histories
 - Behavioral problems
 - Anxiety and mood problems
- > Most will never develop a true psychotic illness



ATYPICAL PSYCHOTIC SYMPTOMS

- Situationally specific
 - Emerge when angry, serve to engage others, only occur at certain times (bedtime, when in trouble, etc...)
- Highly descriptive
 - Organized detailed descriptions
 - Colors, clothing, facial descriptions, etc...
 - Less likely true psychosis
- Trauma Related
- Not associated with other overt psychotic symptoms (i.e., clear thinking, no bizarre, disorganized behaviors)



Treatment Strategies

- Psychopharmacology
 - Antipsychotic agents only specific treatment with documented effectiveness for psychotic symptoms
- Psychosocial Treatments
 - Psychoeducation
 - Cognitive/symptom remediation
 - Family Support
 - Relapse Prevention
 - Intensive Community Support

AACAP 2013



ANTIPSYCHOTICS

- ☐ Start with an FDA approved agent for adolescents
- Medication choice based on side effect profile, patient and family preference, clinician familiarity and cost

- Risperidone, Aripiprazole, Quetiapine (ages 13 years and older) most often used
- Ziprasidone, Amisulpride not effective in large trial of adolescents
- Olanzapine FDA approved for schizophrenia in adolescents, but associated with substantial weight gain
- Clozapine for treatment resistant cases
- Newer ≠ Better



EARLY ONSET SCHIZOPHRENIA TREATMENT GUIDELINES

Regardless of antipsychotic medication choice

- □ Side effect monitoring, including extrapyramidal side effects and metabolic status
 - Baseline: assess patient's and family history of obesity, diabetes, cardiovascular disease, dyslipidemia, or hypertension
 - BMI at baseline, 4, 8, and 12 weeks, and q3months
 - Fasting glucose, lipid profile, and blood pressure:
 - Baseline and after 3 months of treatment. If normal, then annually.
 - Systematic monitoring for abnormal movements (e.g, AIMS exam)



EARLY PSYCHOSIS DETECTION AND INTERVENTION

- Community and Statewide efforts to enhance early detection and treatment of first episode psychosis
 - Education of providers, families and community
 - Assertive treatment (case management, crisis intervention)
 - Integrate multidisciplinary specialty teams into community systems of care
- Improved Functional Outcomes
- Reduced rates of hospitalization
- > Greater adherence to treatments

McFarlane et al., 2015; Schottle et al., 2014

